Modified hyaluronic acid polymer compositions and related methods
The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.
1. A composition comprising crosslinked hydrogel particles in a solution of hyaluronic acid in saline, where the hydrogel particles are formed by reaction of polyethylene glycol dithiol (PEG-dithiol) with hyaluronic acid having 1-10% of its hydroxyl groups derivatized with 2-(vinylsulfonyl)ethoxy groups.
2. The composition of claim 1 , wherein the crosslinked hydrogel particles are suspended in the solution of hyaluronic acid in saline.
3. The composition of claim 1 , wherein the composition is sterile.
4. The composition of claim 1 packaged in a syringe.
5. The composition of claim 1 where the hydrogel particles further comprise a corticosteroid.
6. The composition of claim 1 , wherein the hyaluronic acid having 1-10% of its hydroxyl groups derivatized with 2-(vinylsulfonyl)ethoxy possesses a molecular weight ranging from about 5000 to about 3 million daltons.
7. The composition of claim 1 , wherein the PEG dithiol possesses a molecular weight ranging from about 250 to about 20,000 daltons.
8. The composition of claim 5 , wherein the corticosteroid is triamcinolone acetonide.
9. The composition of claim 8 , wherein the hydrogel particles comprise from about 0.1 to 1% percent by weight (wt/wt) triamcinolone acetonide.
10. The composition of claim 1 , wherein the hydrogel particles have sizes ranging from about 0.10 to 3.0 millimeters.
11. The composition of claim 1 , wherein the hydrogel particles possess a percent by weight (wt/wt) of polymer to water ranging from about 0.5 to 5.0 percent.
12. The composition of claim 1 , extrudable through a 21 gauge needle.
13. The composition of claim 8 , which when administered into an intra-articular space of a joint, has reduced undesirable side effects on the cartilage as compared to the intra-administration into an intra-articular space of a joint of an equivalent amount of triamcinolone acetonide absent of hydrogel incorporation, as indicated by a relatively lower degree of proteoglycan specific staining loss of the cartilage.
14. A method of administering a therapeutic composition, comprising administering the composition of claim 1 into an intra-articular space of a joint of a subject.
15. The method of claim 14 , where the hydrogel particles of the composition of claim 1 further comprise triamcinolone acetonide.
16. A method for reducing one or more undesirable side effects on cartilage upon administration of triamcinolone acetonide into an intra-articular space of a joint of a subject suffering from osteoarthritis by incorporating the triamcinolone acetonide into a cross-linked hydrogel composition in accordance with claim 8 .
17. A method for forming a composition in accordance with claim 1 , comprising reacting a solution of hyaluronic acid having 1-10% of its hydroxyl groups derivatized with 2-(vinylsulfonyl)ethoxy groups with PEG dithiol under reaction conditions effective to form crosslinked hydrogel particles, and suspending the hydrogel particles in a saline solution of hyaluronic acid.
18. The method of claim 17 , comprising:
reacting (i) a solution of hyaluronic acid having 1-10% of its hydroxyl groups derivatized with 2-(vinylsulfonyl)ethoxy groups, wherein the solution comprises particles of triamcinolone acetonide, with (ii) PEG dithiol, under reaction conditions effective to form crosslinked hydrogel particles comprising triamcinolone acetonide, and suspending the hydrogel particles in a saline solution of hyaluronic acid.
19. The method of claim 17 , carried out under aseptic conditions in which all the solution components are sterile filtered prior to the reacting step to thereby form a sterile composition.
20. The method of claim 18 , carried out under aseptic conditions in which all the solution components are sterile filtered prior to the reacting step, and wherein the triamcinolone acetonide is sterile, to thereby form a sterile composition.